Net Income

Backed by a major investment from Nuveen, TurnClear launches to offer water 'Treatment-as-a-Service,' helping industries cut costs and meet regulations.

In a bold Super Bowl move, Rocket and Redfin are skipping the hard sell to deliver a powerful message on neighborliness. Is this the future of marketing?

After a bitter legal battle across Europe, Maxeon and Aiko sign a landmark patent agreement, reshaping the global market for high-efficiency solar tech.

Mawson Infrastructure reports a steep Q4 revenue drop but a smaller annual loss, clearing major legal hurdles to focus on its AI and green energy future.

As Alberta prepares its regulated iGaming market, BetRivers launches pre-registration and unveils an exclusive Olympic partnership with national broadcaster CBC.

The Nutella maker posts strong growth, but its acquisitions of Kellogg's cereals and Power Crunch signal a bold new strategy beyond confectionery.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

With battery fires on the rise, Wanxiang A123 has unveiled a new semi-solid-state and immersion-cooled system designed to eliminate thermal runaway.

One Port St. opens with 5-star amenities, but its arrival in the creative Northern Quarter raises questions about regeneration and the city's future.

ACG becomes the first pharma packaging firm in the WEF's elite Lighthouse Network, using AI to slash defects and energy use, setting a new global standard.

With only 20% of Aussie SMEs insured against cyber threats, Cowbell and Zurich launch an AI-powered platform to simplify and expand coverage.

Ascentage Pharma's next-gen BTK degrader, APG-3288, receives dual IND clearance, paving the way for clinical trials to fight resistant blood cancers.

MGM Resorts moved its earnings date up, and now we know why. The gaming giant beat Wall Street estimates with powerful results from BetMGM and Macau.

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

Facing a stock slump and operational woes, Clorox leaders must deliver a convincing turnaround plan at the upcoming CAGNY investor conference.

Amid financial headwinds, specialty chemicals firm Orion S.A. will pitch its strategic pivot to the high-growth EV and sustainable materials markets.

Viking Therapeutics' upcoming earnings call is about more than just financials. Investors are focused on key pipeline updates for its obesity and MASH drugs.

Angel Oak Mortgage REIT declared a hefty $0.32 dividend, boasting a 14% yield. But can its earnings sustain the payout in the evolving non-QM market?

As Churchill Capital XI's shares and warrants begin separate trading, what does this mean for investors and the hunt for Michael Klein's next big deal?

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?